广告
药物发现
药物开发
优先次序
药品
计算机科学
化学空间
计算生物学
中枢神经系统
药理学
风险分析(工程)
医学
生化工程
生物信息学
神经科学
生物
工程类
管理科学
作者
Travis T. Wager,Xinjun Hou,Patrick R. Verhoest,Anabella Villalobos
标识
DOI:10.1021/acschemneuro.6b00029
摘要
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI